Loading
companiesCompany
Curesponse
Israeli company whose cResponse test keeps a patient's tumour fragment alive, with its vessels and immune cells, to test which treatments it responds to.
Overview
Curesponse, based in Rehovot, Israel, and founded in 2018, is the company whose cResponse test keeps a fragment of a patient's tumour alive, with its blood vessels and immune cells intact, to test which treatments it responds to. The test combines ex vivo tumour-fragment culture with rapid genomics; a 2026 clinical utility study showed the assay can rule out ineffective regimens and reclassify predicted non-responders, and it is distributed in the United Kingdom through EDX Medical. OnCo links it to functional ex vivo drug testing and organoid-guided therapy at scale, to the bottleneck of preclinical models that do not predict people, and to ideas on testing drugs on freshly cut slices of the patient's own tumour. Whether functional testing improves outcomes in a randomised trial is the open question for the whole field. The functional testing page carries the evidence.
Similar pages
- CompanySEngine Precision Medicine
Shares Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Test drugs on the patient's own cancer cells when there is no trial to join.
- CompanyXilis
Shares Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Test drugs on the patient's own cancer cells when there is no trial to join.
- TechnologyPDAC organoid pharmacotyping
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico.
- CompanyChampions Oncology
Shares Test drugs on the patient's own cancer cells when there is no trial to join, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Lab models that fail to predict what happens in patients.
- TechnologyBH3 profiling (functional apoptosis testing)
Shares Test drugs on the patient's own cancer cells when there is no trial to join, Functional (ex vivo) drug testing, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Lab models that fail to predict what happens in patients.
- IdeaPatient-derived organoids to pick ADC payloads
Shares Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
- TechnologyEx vivo drug sensitivity screening in blood cancers (EXALT)
Shares Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Functional (ex vivo) drug testing.
- IdeaZebrafish avatars for a drug answer within a week
Shares Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.